Generics in Europe

Abstract

The generics industry in Europe has been at the forefront along with the United States in pushing the envelope and garnering support from cash-strapped governments to utilize the savings potential of generics in curtailing the overall healthcare spend. However, as we look to the next decade, the cost argument will remain important but will not be the sole mechanism to drive growth and create sustainability that is critical for the industry’s health. This article talks about four fundamental shifts that are shaping the future of the generics industry in Europe and what companies are doing to stay on top.